IMRIS VISIUS

August 12, 2012 By Leave a Comment

Byron Capital Healthcare and Biotech analyst Douglas Loe says his aggressively postitive view that IMRIS's order flow can ramp up is based on the value proposition the company's products offer to hospital clients, which he believes are more than compelling.

Byron Capital Healthcare and Biotech analyst Douglas Loe says his aggressively postitive view that IMRIS’s order flow can ramp up is based on the value proposition the company’s products offer to hospital clients, which he believes are more than compelling.

Filed Under:
About Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.